![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsors and Collaborators: |
Children's Oncology Group National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00436696 |
RATIONALE: Identifying genes related to cancer may help in the study of cancer. It may also help doctors predict who is at risk of developing neuroblastoma.
PURPOSE: This laboratory study is looking at genes in participants with neuroblastoma or noncancerous conditions.
Condition | Intervention |
---|---|
Neuroblastoma |
Genetic: gene mapping Genetic: polymorphism analysis |
Study Type: | Observational |
Official Title: | Genetic Basis of Neuroblastoma Tumorigenesis |
Estimated Enrollment: | 9350 |
Study Start Date: | December 2006 |
Estimated Primary Completion Date: | November 2010 (Final data collection date for primary outcome measure) |
OBJECTIVES:
OUTLINE: This is a multicenter study. Participants are stratified according to presence of high-risk disease (yes vs no) and MYCN amplification (yes vs no).
DNA samples are derived from participants' banked blood or uninvolved bone marrow. A whole genome scan of DNA samples is employed to identify candidate single nucleotide polymorphisms (SNPs). The candidate SNPs are investigated, using a gene-centric haplotyping approach, to identify 10-20 true disease-associated alleles. The disease-associated alleles are again investigated, using a gene-centric haplotyping approach, to validate 5-10 disease-associated SNPs. SNPs are then analyzed for heritable predisposition.
Patients do not receive the results of the genetic testing.
A certificate of confidentiality protecting the identity of research participants in this project has been issued by the Children's Oncology Group.
PROJECTED ACCRUAL: A total of 4,675 patients and 4,675 controls will be accrued for this study.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
DISEASE CHARACTERISTICS:
Patient:
Diagnosis of neuroblastoma
Control (age, race, and gender-matched):
May have other conditions, including any of the following:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
United States, Mississippi | |
University of Mississippi Cancer Clinic | Recruiting |
Jackson, Mississippi, United States, 39216-4505 | |
Contact: Gail C. Megason 601-984-5220 |
Study Chair: | John M. Maris, MD | Children's Hospital of Philadelphia |
Study ID Numbers: | CDR0000522985, COG-ANBL06B1 |
Study First Received: | February 15, 2007 |
Last Updated: | February 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00436696 History of Changes |
Health Authority: | Unspecified |
disseminated neuroblastoma localized resectable neuroblastoma localized unresectable neuroblastoma recurrent neuroblastoma regional neuroblastoma |
Neuroectodermal Tumors Neuroectodermal Tumors, Primitive Neoplasms, Germ Cell and Embryonal Neuroepithelioma |
Neuroectodermal Tumors, Primitive, Peripheral Recurrence Neuroblastoma Neoplasms, Glandular and Epithelial |
Neuroectodermal Tumors Neoplasms Neoplasms by Histologic Type Neuroectodermal Tumors, Primitive Neoplasms, Germ Cell and Embryonal |
Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors, Primitive, Peripheral Neuroblastoma Neoplasms, Glandular and Epithelial |